RESHAPE LIFESCIENCES INC (RSLS)

US76090R2004 - Common Stock

4.38  -0.09 (-2.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RSLS. RSLS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While RSLS seems to be doing ok healthwise, there are quite some concerns on its profitability. RSLS is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

RSLS had negative earnings in the past year.
In the past year RSLS has reported a negative cash flow from operations.
In the past 5 years RSLS always reported negative net income.
In the past 5 years RSLS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of RSLS (-125.86%) is worse than 87.70% of its industry peers.
RSLS's Return On Equity of -475.25% is on the low side compared to the rest of the industry. RSLS is outperformed by 87.70% of its industry peers.
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROIC N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RSLS has a better Gross Margin (68.19%) than 76.47% of its industry peers.
RSLS's Gross Margin has improved in the last couple of years.
RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%

More info and screens

5

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RSLS has less shares outstanding than it did 1 year ago.
RSLS has more shares outstanding than it did 5 years ago.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RSLS has an Altman-Z score of -162.26. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RSLS (-162.26) is worse than 95.72% of its industry peers.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -162.26
ROIC/WACCN/A
WACC9.21%

2.3 Liquidity

RSLS has a Current Ratio of 1.33. This is a normal value and indicates that RSLS is financially healthy and should not expect problems in meeting its short term obligations.
RSLS has a Current ratio of 1.33. This is amonst the worse of the industry: RSLS underperforms 83.42% of its industry peers.
RSLS has a Quick Ratio of 1.33. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.60, RSLS is doing worse than 93.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 0.6

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.65% over the past year.
RSLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.59%.
RSLS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.95% yearly.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%

3.2 Future

The Earnings Per Share is expected to grow by 41.36% on average over the next years. This is a very strong growth
Based on estimates for the next years, RSLS will show a quite strong growth in Revenue. The Revenue will grow by 16.06% on average per year.
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RSLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

RSLS's earnings are expected to grow with 41.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RSLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (12/20/2024, 8:00:01 PM)

4.38

-0.09 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners81.7%
Inst Owner Change-94.58%
Ins Owners26.67%
Ins Owner Change0%
Market Cap3.11M
Analysts43.33
Price TargetN/A
Short Float %3.5%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.59%
Min Revenue beat(2)-12.78%
Max Revenue beat(2)-10.4%
Revenue beat(4)0
Avg Revenue beat(4)-11.15%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)-9.41%
Revenue beat(8)0
Avg Revenue beat(8)-10.55%
Revenue beat(12)0
Avg Revenue beat(12)-14.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-205.92
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-8.74
FCFYN/A
OCF(TTM)-8.73
OCFYN/A
SpS11.53
BVpS2.09
TBVpS2.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.19%
FCFM N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
F-Score5
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 0.6
Altman-Z -162.26
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)17.25%
Cap/Depr(5y)28.26%
Cap/Sales(3y)1.41%
Cap/Sales(5y)4.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.44%
OCF growth 3YN/A
OCF growth 5YN/A